Cimellaro, A.; Addesi, D.; Cavallo, M.; Spagnolo, F.; Suraci, E.; Cordaro, R.; Spinelli, I.; Passafaro, F.; Colosimo, M.; Pintaudi, M.;
et al. Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study. Biomedicines 2022, 10, 3135.
https://doi.org/10.3390/biomedicines10123135
AMA Style
Cimellaro A, Addesi D, Cavallo M, Spagnolo F, Suraci E, Cordaro R, Spinelli I, Passafaro F, Colosimo M, Pintaudi M,
et al. Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study. Biomedicines. 2022; 10(12):3135.
https://doi.org/10.3390/biomedicines10123135
Chicago/Turabian Style
Cimellaro, Antonio, Desirée Addesi, Michela Cavallo, Francesco Spagnolo, Edoardo Suraci, Raffaella Cordaro, Ines Spinelli, Francesco Passafaro, Manuela Colosimo, Medea Pintaudi,
and et al. 2022. "Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study" Biomedicines 10, no. 12: 3135.
https://doi.org/10.3390/biomedicines10123135
APA Style
Cimellaro, A., Addesi, D., Cavallo, M., Spagnolo, F., Suraci, E., Cordaro, R., Spinelli, I., Passafaro, F., Colosimo, M., Pintaudi, M., Pintaudi, C., & on behalf of the CATAnzaro LOng COVID (CATALOCO) Study Group.
(2022). Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study. Biomedicines, 10(12), 3135.
https://doi.org/10.3390/biomedicines10123135
